Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 102Lung Neoplasms 39Neoplasms 11Neoplasm Metastasis 11Colorectal Neoplasms 9Parkinson Disease 4, Autosomal Dominant Lewy Body 6Pancreatic Neoplasms 6Mesothelioma, Malignant 5Mesothelioma 5Carcinoma 5Ovarian Neoplasms 4Meningeal Carcinomatosis 4Melanoma 4Colonic Neoplasms 4Advanced Solid Tumors 4Rectal Neoplasms 3Adenocarcinoma of Lung 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Non-squamous Non-small Cell Lung Cancer 2Neoplasms by Site 2Lung Diseases 2Gastrointestinal Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2Carcinoma, Pancreatic Ductal 2Carcinoma, Bronchogenic 2Bronchial Neoplasms 2Brain Neoplasms 2

Interventions

Cisplatin 15Gemcitabine 14durvalumab 9pembrolizumab 7Oxaliplatin 6Bevacizumab 6Capecitabine 5lenvatinib 4S 1 (combination) 3Liquid Biopsy 3Irinotecan 3Folfox protocol 3Fluorouracil 3Carboplatin 3zanidatamab 2tremelimumab 2envafolimab 2Trastuzumab 2Nivolumab 2Leucovorin 2Injections 2Blood Specimen Collection 2Albumin-Bound Paclitaxel 2trastuzumab deruxtecan 1toripalimab 1tislelizumab 1poly ICLC 1niraparib 1neratinib 1larotrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × Pemetrexed × 90 days × Clear all
NCT04956640 2026-05-29

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Eli Lilly and Company

Phase 1/2 Active not recruiting
540 enrolled
GastrointestinalGynecologicThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡